Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Other Non-Current Liabilities: 2019-2025

Historic Other Non-Current Liabilities for Allogene Therapeutics (ALLO) over the last 7 years, with Sep 2025 value amounting to $15.5 million.

  • Allogene Therapeutics' Other Non-Current Liabilities rose 101.87% to $15.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.5 million, marking a year-over-year increase of 101.87%. This contributed to the annual value of $7.8 million for FY2024, which is 49.86% up from last year.
  • Per Allogene Therapeutics' latest filing, its Other Non-Current Liabilities stood at $15.5 million for Q3 2025, which was up 2.37% from $15.1 million recorded in Q2 2025.
  • In the past 5 years, Allogene Therapeutics' Other Non-Current Liabilities registered a high of $15.5 million during Q3 2025, and its lowest value of $2.8 million during Q1 2021.
  • Over the past 3 years, Allogene Therapeutics' median Other Non-Current Liabilities value was $7.6 million (recorded in 2024), while the average stood at $8.3 million.
  • As far as peak fluctuations go, Allogene Therapeutics' Other Non-Current Liabilities skyrocketed by 156.93% in 2022, and later dropped by 27.42% in 2023.
  • Quarterly analysis of 5 years shows Allogene Therapeutics' Other Non-Current Liabilities stood at $7.8 million in 2021, then fell by 24.96% to $5.8 million in 2022, then declined by 11.42% to $5.2 million in 2023, then skyrocketed by 49.86% to $7.8 million in 2024, then surged by 101.87% to $15.5 million in 2025.
  • Its Other Non-Current Liabilities stands at $15.5 million for Q3 2025, versus $15.1 million for Q2 2025 and $11.3 million for Q1 2025.